Real Humira competition may not arrive until 2026, AbbVie execs tell investors

The best-sell­ing drug of all time will soon face nine com­pet­ing biosim­i­lars, with some priced as much as 86% less than the brand-name ver­sion. But Ab­b­Vie ex­ec­u­tives are con­fi­dent they’re go­ing to con­tin­ue to pro­tect their mar­ket share un­til 2025 or 2026.

When asked about Hu­mi­ra’s longer-term tail in rev­enue on to­day’s earn­ings call, Ab­b­Vie pres­i­dent and COO Rob Michael said the “tail” will “start to emerge in the 2025 or 2026 time­frame.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.